CSIMarket Company Name, Ticker, Industry, else..
 
Vincerx Pharma Inc   (VINC)
 
Price: $0.0150 $0.00 0.000%
Day's High: $0.014999999664723873 Week Perf: 15.38 %
Day's Low: $ 0.01 30 Day Perf: 15.38 %
Volume (M): 300 52 Wk High: $ 0.07
Volume (M$): $ 0 52 Wk Avg: $0.02
Open: $0.01 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 4
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Vincerx Pharma Inc is a biopharmaceutical company focused on the development and commercialization of next-generation targeted therapies for various forms of cancer. The company's mission is to provide innovative treatment options to patients with limited or no effective treatment choices. Vincerx Pharma aims to address unmet medical needs by advancing novel drug candidates through rigorous research and development processes. The company is committed to improving patient outcomes and quality of life by leveraging its expertise in precision medicine and targeted therapeutics.


   Company Address: 1825 S. Grant Street San Mateo 94402 CA
   Company Phone Number: 800-6676   Stock Exchange / Ticker: VINC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -1.48%    
EBS        4.51% 
OPK   -1.57%    
PFE   -0.86%    
RCUS   -19.17%    
REGN   -4.23%    
• View Complete Report
   



Merger and Acquisition

Vincerx Pharma’s Strategic Step into AI: A Potential Game-Changer for Cancer Treatment and Shareholder Value

Published Tue, Mar 18 2025 12:53 PM UTC

In a significant announcement for the biotechnology sector, Vincerx Pharma, Inc. (NASDAQ: VINC) has declared its entry into a non-binding letter of intent (LOI) for a business combination with Global Digital Holdings Inc. operating as QumulusAI. This development, dated March 18, 2025, represents a strategic pivot for Vincerx, a company traditionally focused on advancing nove...
Stock Market Announcement

Vincerx Pharma Signals Strategic Advancement with Reverse Stock Split and Oncology Partnership with Oqory, Inc.

Published Thu, Jan 23 2025 9:05 PM UTC

Vincerx Pharma, Inc. a biopharmaceutical company committed to innovation in the treatment of hematologic and solid tumor cancers, is poised for a significant strategic transformation. On January 28, 2025, Vincerx announced a reverse stock split of its common stock. This move is set to recalibrate the company s stock fundamentals, preparing the way for future growth and inves...
Merger and Acquisition

Vincerx Pharma and Oqory, Inc. Join Forces: Highlighting the Promising Data for Oqory’s TROP2 Antibody-Drug Conjugate, OQY-3258,

Published Wed, Jan 29 2025 1:00 PM UTC

Vincerx Pharma and Oqory, Inc. Forge Strategic Merger to Enhance Oncology PipelineOn December 27, 2024, Vincerx Pharma, Inc. announced that it has entered into a binding term sheet for a strategic merger with Oqory, Inc. a move poised to substantially bolster Vincerx s oncology pipeline, particularly with the integration of Oqory’s promising Phase 3 TROP2 antibody-drug co...
Merger and Acquisition

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. to Augment Pipeline with Phase 3 TROP2 ADC.

Published Fri, Dec 27 2024 9:05 PM UTC

Amidst a challenging landscape for biotechnology companies, Vincerx Pharma, Inc. (NASDAQ: VINC) is reportedly in discussions for a significant strategic merger with Oqory, Inc. a move that could reshape its product pipeline significantly.Vincerx, whose business model emphasizes the development and commercialization of novel small molecule drugs for cancer treatment, aims to ...
Clinical Study

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipelin...

Published Mon, Oct 7 2024 8:06 PM UTC

Vincerx Pharma s Promising Advances: VIP943 Shows Initial Clinical Success and Future Potential in Cancer TreatmentIn a landscape where innovative therapies remain crucial to improving patient outcomes, Vincerx Pharma has charted a noteworthy path with its investigational therapies, particularly VIP943. Recent announcements have underscored the potential of this novel CD123...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.03
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.69
Working Capital Ratio 1.79
Leverage Ratio (MRQ) 1.27
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -17.72 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 1.24 $
Book Value 0.58 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,887,083
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.